Product approval from flagship facility in Bangalore

To be marketed by Strides Pharma Inc. in the US market

MUMBAI, JUNE 02, 2020 (GPN)- Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Ointment USP,0.05%from the United States Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 15 Mn. The product will be manufactured at thecompany’s flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the USmarket.

The company has 124 cumulative ANDA filings with USFDA of which 86 ANDAs have been

approved and 38 are pending approval.

About Triamcinolone Acetonide Ointment

Triamcinolone Acetonide Ointment 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ENDS

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India.  The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website atwww.strides.com